Journal
ARCHIVES OF PHARMACAL RESEARCH
Volume 33, Issue 7, Pages 1127-1132Publisher
PHARMACEUTICAL SOC KOREA
DOI: 10.1007/s12272-010-0720-5
Keywords
Human gastric cancer; Cisplatin resistance; p53; Bax; p21; p27
Categories
Funding
- Korean Government (MOEHRD) [531-2007-1-E00110]
Ask authors/readers for more resources
The major obstacle of treating cancer patients is acquisition of chemoresistance, in which treated tumor cells become insensitive after chronic drug exposure. To study the mechanism of acquired cisplatin resistance, we established a cisplatin-resistant human gastric cancer cell line. The cisplatin-resistant cell line (YCC-3/R) was isolated after exposing the gastric cancer cell line, YCC-3, to a constant concentration (0.5 mu g/mL) of cisplatin for 12 months. The expression of cell cycle regulatory proteins (p53, Bax, p21, p27) in the YCC-3/R were investigated by western blot analysis. The cisplatin treatment significantly down-regulated the p53 and p21 expression level, while up-regulated the p27 expression in the YCC-3/R cells compared to the parental cells. The Bax expression level was similar in both cells. These results suggest that the p27 dependent-cell cycle arrest may prevent cisplatin-induced apoptosis and give enough time to repair the DNA damage in the YCC-3/R cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available